Biomarker panel (TheraPrint) analyzed as a predictor of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. This is an ASCO Meeting Abstract from the 2014 ASCO Annual ...
MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells, enhancing antitumor activity and reducing antigen loss. The therapy's design limits cytokine release syndrome, showing improved ...
At a median follow-up of 10.7 months, the overall response rate was 63.1%. The subcutaneous CD3xCD20 bispecific T-cell–engaging antibody epcoritamab (Epkinly) leads to deep and durable responses in ...
CD20, a transmembrane calcium channel required for B cell activation, proliferation, and differentiation, has emerged as a key therapeutic target for B-cell malignancies and autoimmune disorders. Its ...
– Phase 1 healthy volunteer study of half-life extended anti-TL1A antibody XmAb942 to dose first subject in Q4 2024, with data anticipated in the first half of 2025 – – XmAb® T-cell engagers ...
Cytokine release syndrome (CRS), all grades, is observed in approximately 55%-80% of the patients with relapsed or refractory multiple myeloma and 45%-65% of the patients with B-cell non-Hodgkin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results